

AKUMS DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

+91-11-69041000

CIN: L24239DL2004PLC125888

www.akums.in

akumsho@akums.net

+91-11-27023256

Ref: Akums/Exchange/2026-27/16

May 20, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai - 400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: Receipt of Assessment Order(s) from Income Tax Department

Ref: Disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Respected Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("**SEBI LODR Regulations**") this is to inform you that Akums Drugs and Pharmaceuticals Limited ("**the Company**") and Akumentis Healthcare Ltd., a subsidiary of the Company ("**AHL**") have received assessment order(s) under Section 158BC of the Income Tax Act, 1961 for the block period starting from 01.04.2018 to 12.03.2025.

The details required to be furnished under Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and as per the terms of Industry Standards Note on Regulation 30 of SEBI LODR Regulations issued vide SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/25 dated February 25, 2025 are annexed as "**Annexure-A**" and "**Annexure-B**", respectively.

You are requested to kindly take the above information on your records.

Thanking You

Yours Faithfully

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: As Above

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

Annexure-A

Disclosure under Regulation 30 read with Clause 20 of Para A of Part A of Schedule III of SEBI LODR Regulations:

Sr. No.	Details of event that needs to be provided	Details	
Name of the Company(ies)		Akums Drugs and Pharmaceuticals Limited ("the Company")	Akumentis Healthcare Limited ("AHL")
1.	Name of the authority	Income Tax Department, Office of the Deputy Commissioner of Income Tax, Central Circle 1, New Delhi ("IT Authority")	Income Tax Department, Office of the Deputy Commissioner of Income Tax, Central Circle 1, New Delhi ("IT Authority")
2.	Nature and details of the action(s) taken, initiated or order(s) passed;	The Company has received the assessment order under section 158BC of the Income Tax Act for the block period starting from 01.04.2018 to 12.03.2025. The demand of Rs. 60,09,22,342/- has been received, on account of disallowance of various expenditures u/s 37(1) of the Act.	AHL has received the assessment order under section 158BC of the Income Tax Act for the block period starting from 01.04.2018 to 12.03.2025. The demand of Rs. 73,66,10,238/- has been received, on account of disallowance of various expenditures u/s 37(1) of the Act.
3.	Date of receipt of direction or order, including any ad-interim or interim order, or any other communication from the authority;	Order dated May 20, 2026 (received on May 20, 2026)	Order dated May 19, 2026 (received on May 20, 2026)
4.	Details of the violation(s)/ contravention(s) committed or alleged to be committed;	Disallowances has been done majorly on account of various expenditure under Section 37(1) of the Income Tax Act, 1961	Disallowances has been done on account of various expenditure under Section 37(1) of the Income Tax Act, 1961
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	Based on our internal assessment, the Company does not expect the said order to have any material financial impact since the aforementioned demand is not sustainable in the law and are defendable on the facts of the case. The Company would pursue appeal against the said order under the applicable laws.	Based on our internal assessment, AHL does not expect the said order to have any material financial impact since the aforementioned demand is not sustainable in the law and are defendable on the facts of the case. AHL would pursue appeal against the said order under the applicable laws.

Annexure-B

Disclosure of information pursuant to Regulation 30(13) of SEBI LODR Regulations and Industry Standards Note on Regulation 30 of SEBI LODR Regulations issued vide SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/25 dated February 25, 2025 regarding receipt of communication from regulatory, statutory, enforcement or judicial authority:

Sr. No.	Particulars	Details
1.	Name of the Listed Company	Akums Drugs and Pharmaceuticals Limited ("the Company")
2.	Type of communication received	Assessment Order under Section 158BC of the Income Tax Act, 1961 for the block period starting from 01.04.2018 to 12.03.2025 received from the IT Authority
3.	Date of receipt of communication	Assessment Order dated May 20, 2026 (received on May 20, 2026)
4.	Authority from whom communication received	Income Tax Department, Office of the Deputy Commissioner of Income Tax, Central Circle 1, New Delhi
5.	Brief summary of the material contents of the communication received, including reasons for receipt of the communication	The Company has received the assessment order under section 158BC of the Income Tax Act for the block period starting from 01.04.2018 to 12.03.2025 from IT Authority. The demand is of Rs. 60,09,22,342/- raised is on account of disallowance of various expenditures under Section 37(1) of the Income Tax Act, 1961
6.	Period for which communication would be applicable, if stated	Block Period: starting from 01.04.2018 to 12.03.2025
7.	Expected financial implications on the listed company, if any	Based on our internal assessment, the Company does not expect the said order to have any material financial impact since the aforementioned adjustments are not sustainable in the law and are defensible on the facts of the case. The Company would pursue appeal against the said order under the applicable laws.
8.	Details of any aberrations/non-compliances identified by the authority in the communication	Section 37(1) of the Income Tax Act, 1961
9.	Details of any penalty or restriction or sanction imposed pursuant to the communication	Not Applicable (as the assessment order is in the nature of demand)
10.	Action(s) taken by listed company with respect to the communication	The Company believes that the demand under the above referred Order is not sustainable in the law and are tenable & defensible on the facts of the case. The Company would pursue appeal against the said order under the applicable laws.
11.	Any other relevant information	N.A.